Skip to content

Rapid-acting antidepressant drugs modulate affective bias in rats

Katie Kamenish, Roberto Arban, Aslihan Selimbeyoglu, Shaun Hurley, Bastian Hengerer, Gary Gilmour, Justyna K. Hinchcliffe, Sarah A. Stuart, Christian M. Wood, Julia M. Bartlett, Christopher W. Thomas, Emma Robinson

Science Translational Medicine January 10, 2024 DOI: 10.1126/scitranslmed.adi2403 via OpenAlex

Summary

AI-generated from the abstract

Negative cognitive biases—where mood colors learning and memory—are a core feature of major depressive disorder, and reversing them may be key to how rapid-acting antidepressants work. In rats, a single dose of ketamine, scopolamine, or psilocybin selectively weakened a negative affective bias induced in an associative learning task. Low doses of ketamine and psilocybin, but not high doses, reversed the valence of the bias 24 hours later. Only psilocybin produced a lasting positive bias that depended on new learning. Ketamine's relearning effects required protein synthesis in the medial prefrontal cortex and could be altered by cue reactivation, pointing to experience-dependent neural plasticity as a shared mechanism for both the rapid and sustained effects of these drugs.

Study at a glance

Characteristics Experimental animal study Peer reviewed
Population Rats
Interventions Ketamine Scopolamine Psilocybin
Topics Depression Ketamine Neuroplasticity Psilocybin
Keywords Neuroscience Psychology Antidepressant
Citations 26
Key finding Rapid-acting antidepressants ketamine, scopolamine, and psilocybin attenuate negative affective biases in rats, with low doses of ketamine and psilocybin reversing bias valence through mechanisms involving prefrontal protein synthesis and experience-dependent plasticity.

Abstract

How rapid-acting antidepressants (RAADs), such as ketamine, induce immediate and sustained improvements in mood in patients with major depressive disorder (MDD) is poorly understood. A core feature of MDD is the prevalence of cognitive processing biases associated with negative affective states, and the alleviation of negative affective biases may be an index of response to drug treatment. Here, we used an affective bias behavioral test in rats, based on an associative learning task, to investigate the effects of RAADs. To generate an affective bias, animals learned to associate two different digging substrates with a food reward in the presence or absence of an affective state manipulation. A choice between the two reward-associated digging substrates was used to quantify the affective bias generated. Acute treatment with the RAADs ketamine, scopolamine, or psilocybin selectively attenuated a negative affective bias in the affective bias test. Low, but not high, doses of ketamine and psilocybin reversed the valence of the negative affective bias 24 hours after RAAD treatment. Only treatment with psilocybin, but not ketamine or scopolamine, led to a positive affective bias that was dependent on new learning and memory formation. The relearning effects of ketamine were dependent on protein synthesis localized to the rat medial prefrontal cortex and could be modulated by cue reactivation, consistent with experience-dependent neural plasticity. These findings suggest a neuropsychological mechanism that may explain both the acute and sustained effects of RAADs, potentially linking their effects on neural plasticity with affective bias modulation in a rodent model.

Explore topics

Comments

No comments yet.

Log in to comment